Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tianjin Medical University Cancer Institute and Hospital
For patients with peripheral non-small cell lung cancer receiving stereotactic body radiation therapy, respiratory motion often causes target volume deviation and compromises dose accuracy to tumors and nearby organs at risk. Current standard immobilization methods have limited ability to stabilize deep breathing patterns. This single-center translational study uses an integrated body position and breath-holding device, enrolling 50 eligible patients who will undergo 4DCT scans both with and without the device while keeping their clinical SBRT treatment plan unchanged. We will compare tumor motion amplitude, target coverage, conformity index and organ dose parameters between the two scanning states, to verify the device's feasibility, safety and value in improving treatment precision, providing clinical evidence for wider application in lung SBRT.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Voluntarily participate and sign written informed consent
2. Age ≥18 years, gender unlimited
3. Clinically diagnosed with single peripheral lung cancer, assessed as suitable for SBRT
4. Males or females of childbearing age willing to take contraceptive measures during the trial
5. Female of childbearing age must have a negative pregnancy test within 7 days before treatment, and all patients use adequate contraception during treatment and for 4 weeks after
You may not be if
1. Intolerant or unwilling to receive the integrated respiratory suppression and positioning immobilization device for radiotherapy localization.
2. Currently participating or planning to participate in other clinical trials.
3. Refuse or be unable to sign the informed consent form for this trial.
4. Patients with central or ultra-central lung cancer.
5. Patients planned to receive SBRT for multiple pulmonary lesions.
6. Patients assessed by the investigators of this trial as unsuitable for SBRT treatment.